Cargando…

Botulinum Toxin a Valuable Prophylactic Agent for Migraines and a Possible Future Option for the Prevention of Hormonal Variations-Triggered Migraines

Background: In 1989, Botulinum toxin (BoNT) was accepted by the FDA for the management of some ophthalmic disorders. Although it was initially considered a lethal toxin, in recent times, Botulinum toxin A (BoNT-A), which is the more used serotype, has expanded to cover different clinical conditions,...

Descripción completa

Detalles Bibliográficos
Autores principales: Dima, Lorena, Bălan, Andreea, Moga, Marius Alexandru, Dinu, Cătălina Georgeta, Dimienescu, Oana Gabriela, Varga, Ioana, Neculau, Andrea Elena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6722780/
https://www.ncbi.nlm.nih.gov/pubmed/31398813
http://dx.doi.org/10.3390/toxins11080465
_version_ 1783448618848485376
author Dima, Lorena
Bălan, Andreea
Moga, Marius Alexandru
Dinu, Cătălina Georgeta
Dimienescu, Oana Gabriela
Varga, Ioana
Neculau, Andrea Elena
author_facet Dima, Lorena
Bălan, Andreea
Moga, Marius Alexandru
Dinu, Cătălina Georgeta
Dimienescu, Oana Gabriela
Varga, Ioana
Neculau, Andrea Elena
author_sort Dima, Lorena
collection PubMed
description Background: In 1989, Botulinum toxin (BoNT) was accepted by the FDA for the management of some ophthalmic disorders. Although it was initially considered a lethal toxin, in recent times, Botulinum toxin A (BoNT-A), which is the more used serotype, has expanded to cover different clinical conditions, primarily characterized by neuropathic pain, including migraines and headaches. Evidence suggests that migraines are influenced by hormonal factors, particularly by estrogen levels, but very few studies have investigated the prevalence and management strategies for migraines according to the hormonal status. The effects of several therapeutic regimens on migraines have been investigated, but the medications used varied widely in proven efficacies and mechanisms of action. BoNT-A is increasingly used in the management of migraine and several placebo-controlled trials of episodic and chronic migraine are currently underway. This paper is a review of the recently published data concerning the administration of BoNT-A in the prevention of chronic migraines. Considering the lack of population-based studies about the effectiveness of BoNT-A in the alleviation of premenstrual and perimenopausal migraines, this study proposes a new perspective of the therapeutic approach of migraine syndrome associated with menopausal transition and the premenstrual period. Methods: We selected the reviewed papers from CrossRef, PubMed, Medline, and GoogleScholar, and a total of 21 studies met our inclusion criteria. Results: To date, no specific preventive measures have been recommended for menopausal women with migraines. BoNT-A often reduces the frequency and intensity of migraine attacks per month; the treatment is well tolerated and does not exhibit a significantly higher rate of treatment-related side effects. No population-based studies were conducted in order to highlight the role of BoNT-A in menopause-related migraines, neither in menstrual migraines. Conclusion: There is a need for further research in order to quantify the real burden of menstrual and perimenopausal migraines and to clarify if BoNT-A could be used in the treatment of refractory postmenopausal and premenstrual migraines.
format Online
Article
Text
id pubmed-6722780
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-67227802019-09-10 Botulinum Toxin a Valuable Prophylactic Agent for Migraines and a Possible Future Option for the Prevention of Hormonal Variations-Triggered Migraines Dima, Lorena Bălan, Andreea Moga, Marius Alexandru Dinu, Cătălina Georgeta Dimienescu, Oana Gabriela Varga, Ioana Neculau, Andrea Elena Toxins (Basel) Review Background: In 1989, Botulinum toxin (BoNT) was accepted by the FDA for the management of some ophthalmic disorders. Although it was initially considered a lethal toxin, in recent times, Botulinum toxin A (BoNT-A), which is the more used serotype, has expanded to cover different clinical conditions, primarily characterized by neuropathic pain, including migraines and headaches. Evidence suggests that migraines are influenced by hormonal factors, particularly by estrogen levels, but very few studies have investigated the prevalence and management strategies for migraines according to the hormonal status. The effects of several therapeutic regimens on migraines have been investigated, but the medications used varied widely in proven efficacies and mechanisms of action. BoNT-A is increasingly used in the management of migraine and several placebo-controlled trials of episodic and chronic migraine are currently underway. This paper is a review of the recently published data concerning the administration of BoNT-A in the prevention of chronic migraines. Considering the lack of population-based studies about the effectiveness of BoNT-A in the alleviation of premenstrual and perimenopausal migraines, this study proposes a new perspective of the therapeutic approach of migraine syndrome associated with menopausal transition and the premenstrual period. Methods: We selected the reviewed papers from CrossRef, PubMed, Medline, and GoogleScholar, and a total of 21 studies met our inclusion criteria. Results: To date, no specific preventive measures have been recommended for menopausal women with migraines. BoNT-A often reduces the frequency and intensity of migraine attacks per month; the treatment is well tolerated and does not exhibit a significantly higher rate of treatment-related side effects. No population-based studies were conducted in order to highlight the role of BoNT-A in menopause-related migraines, neither in menstrual migraines. Conclusion: There is a need for further research in order to quantify the real burden of menstrual and perimenopausal migraines and to clarify if BoNT-A could be used in the treatment of refractory postmenopausal and premenstrual migraines. MDPI 2019-08-08 /pmc/articles/PMC6722780/ /pubmed/31398813 http://dx.doi.org/10.3390/toxins11080465 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Dima, Lorena
Bălan, Andreea
Moga, Marius Alexandru
Dinu, Cătălina Georgeta
Dimienescu, Oana Gabriela
Varga, Ioana
Neculau, Andrea Elena
Botulinum Toxin a Valuable Prophylactic Agent for Migraines and a Possible Future Option for the Prevention of Hormonal Variations-Triggered Migraines
title Botulinum Toxin a Valuable Prophylactic Agent for Migraines and a Possible Future Option for the Prevention of Hormonal Variations-Triggered Migraines
title_full Botulinum Toxin a Valuable Prophylactic Agent for Migraines and a Possible Future Option for the Prevention of Hormonal Variations-Triggered Migraines
title_fullStr Botulinum Toxin a Valuable Prophylactic Agent for Migraines and a Possible Future Option for the Prevention of Hormonal Variations-Triggered Migraines
title_full_unstemmed Botulinum Toxin a Valuable Prophylactic Agent for Migraines and a Possible Future Option for the Prevention of Hormonal Variations-Triggered Migraines
title_short Botulinum Toxin a Valuable Prophylactic Agent for Migraines and a Possible Future Option for the Prevention of Hormonal Variations-Triggered Migraines
title_sort botulinum toxin a valuable prophylactic agent for migraines and a possible future option for the prevention of hormonal variations-triggered migraines
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6722780/
https://www.ncbi.nlm.nih.gov/pubmed/31398813
http://dx.doi.org/10.3390/toxins11080465
work_keys_str_mv AT dimalorena botulinumtoxinavaluableprophylacticagentformigrainesandapossiblefutureoptionforthepreventionofhormonalvariationstriggeredmigraines
AT balanandreea botulinumtoxinavaluableprophylacticagentformigrainesandapossiblefutureoptionforthepreventionofhormonalvariationstriggeredmigraines
AT mogamariusalexandru botulinumtoxinavaluableprophylacticagentformigrainesandapossiblefutureoptionforthepreventionofhormonalvariationstriggeredmigraines
AT dinucatalinageorgeta botulinumtoxinavaluableprophylacticagentformigrainesandapossiblefutureoptionforthepreventionofhormonalvariationstriggeredmigraines
AT dimienescuoanagabriela botulinumtoxinavaluableprophylacticagentformigrainesandapossiblefutureoptionforthepreventionofhormonalvariationstriggeredmigraines
AT vargaioana botulinumtoxinavaluableprophylacticagentformigrainesandapossiblefutureoptionforthepreventionofhormonalvariationstriggeredmigraines
AT neculauandreaelena botulinumtoxinavaluableprophylacticagentformigrainesandapossiblefutureoptionforthepreventionofhormonalvariationstriggeredmigraines